Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the highest amount of peldesine that is safe. This study will also see if this amount of peldesine is effective in lowering HIV levels in the blood.
Full description
Patients are given either BCX-35 or placebo for 14 or 28 days. Plasma viral load will be determined at the MTD.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Concomitant therapy with other medications having primary renal excretion (other than 3TC, ddC, and d4T).
Prior Medication:
Excluded:
Required:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal